Belluscura announces filing of a patent application on an oxygen enrichment device and system for treating acute respiratory distress (ARDS), including ARDS caused by the recent Coronavirus

BelluscuraNews

LONDON, UK AND PLANO, TX, February 6, 2020.  Belluscura PLC, in conjunction with its exclusive research partner Separation Design Group, announced today the filing of a patent application covering novel integrated portable extracorporeal oxygenation and carbon dioxide removal systems for treating patients suffering from acute respiratory distress syndrome (ARDS).

The latest patent application covers devices and systems for treating people suffering from ARDS including patients suffering from the recent coronavirus in Wuhan, China.  The primary cause of death from respiratory viruses like the coronavirus and influenza, are the result of the fluids accumulating inside the alveoli (the tiny air sacs of the lungs) which ultimately leads to the failure of the transfer of oxygen to and carbon dioxide out of the blood.  The current primary treatment for ARDS is oxygen therapy along with ventilator support.

In cases where oxygen therapy and ventilator support are not effective, extracorporeal membrane oxygenation (ECMO), which circulates a patient’s blood through an oxygenation membrane, has been used to remove carbon dioxide from and diffuse oxygen into a patient’s blood while giving a patient’s lungs a chance to recover.  Belluscura and Separation Design are designing and developing next generation, cost-effective, portable ECMO technology to treat ARDS patients.

Commenting on the patenting activities, Bob Rauker, CEO of Belluscura, said: “We are very excited about our next generation oxygen technologies.  With the launch this year of our first product, the X-PLOR™ portable oxygen concentrator, into the respiratory treatment field where over 250 million people suffer from chronic obstructive pulmonary disease (COPD), the third leading cause of death, it is critical that we continue to innovate into the ever-expanding oxygen therapy market”.

Background to Belluscura

Belluscura (www.belluscura.com) was established in the UK in December 2015 with the goal of enriching life through inno2vation.

This Press Release contains forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements are statements regarding the Company’s intentions, beliefs or current expectations concerning, among other things, the Company’s results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future.  These forward-looking statements speak only as of the date of this Press Release and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Press Release.

www.belluscura.com

Contact:               Investor Relations

Name:                  CEO

e-mail:                  investor@belluscura.com

phone:                 1-214-396-8313